Subscribe
istock-839222794-nicoelnino-1
NicoElnino / iStockphoto.com
13 November 2018Americas

CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology

Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
Vertex and CRISPR Therapeutics announce research partnership
26 October 2015   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.


Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
Vertex and CRISPR Therapeutics announce research partnership
26 October 2015   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
Vertex and CRISPR Therapeutics announce research partnership
26 October 2015   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.

More features

Amy Candido joins Simpson Thacher to head ‘powerhouse litigation team’
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
The rise of weight loss drugs: Regulators tighten up
Paul Hastings adds Latham tech transactions expert as co-chair
Why Abbott’s victory marks a turning point for UPC preliminary injunctions
Natera loses $96m jury win as judge invalidates DNA test patents
Fed Circ’s Wuhan v ITC ruling opens ITC door to small corps
Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules